Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
87 hedge funds and large institutions have $76.9M invested in Navidea Biopharmaceuticals Inc. in 2013 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 11 closing their positions.
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
10% more funds holding
Funds holding: 79 → 87 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less capital invested
Capital invested by funds: $90.3M → $76.9M (-$13.3M)
16% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 25
17% less call options, than puts
Call options by funds: $1.04M | Put options by funds: $1.26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.07M |
| 2 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
+$3.91M |
| 3 |
PM
Platinum Management
New York
|
+$1.98M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.57M |
| 5 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$4.63M |
| 2 |
MC
Miles Capital
West Des Moines,
Iowa
|
-$330K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$290K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$243K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$236K |
NAVB Hedge Fund Activity: Q4 2013 in Review
87 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2013, worth a combined $76.9M — down 15% from $90.3M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NAVB positions and 11 closed out — a net gain of 8 holders — while 21 added to existing stakes and 25 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $6.07M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $4.63M sold.
- 87 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2013, up from 79 in Q3 2013.
- Funds reported $76.9M of Navidea Biopharmaceuticals Inc. stock for Q4 2013, down 15% quarter-over-quarter.
- 19 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2013 and 11 closed out, a net change of +8 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2013 was Wellington Management Group, an estimated $6.07M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q4 2013 was JP Morgan Chase, an estimated $4.63M sold.
Based on aggregated 13F filings for Q4 2013.